SCHEMBL2951395

SCHEMBL2951395

COc1ccc(-c2cc3cc4nc(cc5ccc(cc6nc(cc2[nH]3)C=C6)[nH]5)C=C4)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 1/20 0.43
▸ EPHX2 P34913 1/20 0.43
▸ KDM4E B2RXH2 6/20 0.42
▸ ALDH1A1 P00352 5/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ MPI P34949 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ APOBEC3G Q9HC16 1/20 0.42
▸ HPGD P15428 3/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ NCOA2 Q15596 1/20 0.39
▸ NCOA1 Q15788 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5576187 0.89 NOX1 (0.46) GAAGFERPOLBPARP1
SCHEMBL2950385 0.87 BRD4 (0.40) KDM4EALDH1A1TDP1GAAMPI
SCHEMBL29148788 0.86 AMY1A (0.43) ALOX5EPHX2KDM4EALDH1A1TDP1
SCHEMBL31471705 0.84 CDC25A (0.37) ALOX5EPHX2KDM4EGAAHSD17B10
SCHEMBL27891981 0.83 MAPT (0.38) KDM4EHPGDMAPTPOLBSMN1; SMN2
SCHEMBL29915582 0.83 GABRA1 (0.36) ALOX5EPHX2KDM4EALDH1A1GAA
SCHEMBL28442526 0.83 NPC1 (0.40) KDM4EALDH1A1TDP1GAAMPI
SCHEMBL8003382 0.83 NPC1 (0.40) KDM4EALDH1A1TDP1GAAMPI
SCHEMBL28843869 0.83 NPC1 (0.40) KDM4EALDH1A1TDP1GAAMPI
SCHEMBL28098901 0.83 NPC1 (0.40) KDM4EALDH1A1TDP1GAAMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110394189-A A kind of catalyst and preparation method thereof for high efficiency photocatalysis degradation 1,5- dihydroxy naphthlene UNIV BEIJING CHEM TECH 2019-11-01 — — CN claimed
WO-2017051435-A1 CHLORIN BASED COMPOUNDS, A PROCESS FOR PREPARATION THEREOF AND USE AS PHOTODYNAMIC THERAPEUTIC AGENTS AND FLUORESCENT PROBES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2017-03-30 — — WO claimed
EP-2379109-B1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE BAUSCH HEALTH COMPANIES INC (CA) 2020-10-07 — — EP disclosed
CN-110394189-A A kind of catalyst and preparation method thereof for high efficiency photocatalysis degradation 1,5- dihydroxy naphthlene UNIV BEIJING CHEM TECH 2019-11-01 — — CN disclosed
WO-2017051435-A1 CHLORIN BASED COMPOUNDS, A PROCESS FOR PREPARATION THEREOF AND USE AS PHOTODYNAMIC THERAPEUTIC AGENTS AND FLUORESCENT PROBES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2017-03-30 — — WO disclosed
US-20160205925-A1 ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2016-07-21 — — US disclosed
EP-1357912-B9 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QUADRA LOGIC TECH INC (CA) 2012-06-13 — — EP disclosed
US-7850981-B2 Immuno-adjuvant PDT treatment of metastatic tumors QLT, INC. (CA) 2010-12-14 — — US disclosed
US-7753943-B2 Reduced fluence rate PDT QLT INC. (CA) 2010-07-13 — — US disclosed
WO-2010069073-A1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE QLT INC. (CA) 2010-06-24 — — WO disclosed
US-20100040546-A1 Biological targeting compositions and methods of using the same SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE 2010-02-18 — — US disclosed
US-20030099596-A1 Treatment of macular edema BAUSCH HEALTH IRELAND LIMITED (IE) 2003-05-29 — — US disclosed
US-20030087889-A1 Photodynamic therapy of occult age-related macular degeneration BAUSCH HEALTH COMPANIES INC. (CA) 2003-05-08 — — US disclosed
US-20030083649-A1 Method for reducing or preventing PDT related inflammation VALEANT SP. Z.O.O. (PL) 2003-05-01 — — US disclosed
US-20020183302-A1 Method to prevent vision loss TECHNOLAS PERFECT VISION GMBH (DE) 2002-12-05 — — US disclosed
US-20020173832-A1 Reduced fluence rate PDT TECHNOLAS PERFECT VISION GMBH (DE) 2002-11-21 — — US disclosed
US-20020156062-A1 Drug delivery system for hydrophobic drugs BAUSCH HEALTH COMPANIES INC. (CA) 2002-10-24 — — US disclosed
US-20020155089-A1 Drug delivery systems for photodynamic therapy UNIVERSITY OF BRITISH COLUMBIA, THE (CA) 2002-10-24 — — US disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 — — US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030099596-A1 Treatment of macular edema VEGFA, PPOX, FLT4 ALOX5 335/4885EPHX2 2977/4885KDM4E 2230/4885
US-20020183302-A1 Method to prevent vision loss VEGFA, ALDH1A2, PDE6C ALOX5 322/4885EPHX2 3541/4885KDM4E 3259/4885
US-20020156062-A1 Drug delivery system for hydrophobic drugs LIPA, MLEC, ABCG2 ALOX5 865/4885EPHX2 1150/4885KDM4E 3305/4885
US-20020155089-A1 Drug delivery systems for photodynamic therapy PIN1, PPOX, DHFR ALOX5 1108/4885EPHX2 563/4885KDM4E 1989/4885
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA ALOX5 474/4885EPHX2 2534/4885KDM4E 3097/4885
US-20160205925-A1 ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER CUTA, POLR1C, PUF60 ALOX5 1396/4885EPHX2 3210/4885KDM4E 3572/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 ALOX5 267/4885EPHX2 1951/4885KDM4E 4361/4885
US-20030087889-A1 Photodynamic therapy of occult age-related macular degeneration ALDH1A2, AGER, CRY2 ALOX5 896/4885EPHX2 3177/4885KDM4E 3312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback